Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=486c97ac-9a0f-4d49-8efe-5b1c658bf217
Date 9/4/2013
Company Name iPierian
Mailing Address 951 Gateway Blvd South San Francisco, CA 94080
Company Description iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Proceeds Purposes For iPierian, proceeds of the financing will be used to accelerate the clinical development program for IPN007, a monoclonal antibody targeting the Tau protein for the treatment of Alzheimer’s disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). iPierian selected IPN007 based on novel secreted Tau discoveries made using its induced pluripotent stem cell (iPSC) platform.